Abstract 60P
Background
Natural killer (NK) cells are promising tools for immunotherapy of different malignancies including childhood leukaemia and are shown to exhibit memory-like features. Epigenetic alterations including DNA methylation contribute to the generation of memory in these cells. Studying the DNA methylation profile of activated NK cells helps identify candidate genes of activation biomarkers and new approaches to enhance NK cytotoxicity by targeting intrinsic epigenetic regulators.
Methods
We investigated the DNA methylation profile in NK cells upon priming with activating cytokines. Basically, two types of peripheral blood NK cells were used in this study: Freshly antibody-bead isolated NK cells and expanded NK cells, generated by a 7-day coculture with irradiated K562 cells expressing membrane bound IL-21. Memory-like features were achieved by 16-h stimulation of NK cells with IL-12, IL-15, and IL-18, as previously published. The activation of NK cells was confirmed by higher production of Interferon-γ in preactivated cells. DNA was extracted from the FACS sorted NK cells, based on NK cells markers, in both experimental groups and were analysed by Illumina methylation bead array.
Results
Downstream bioinformatic analyses revealed differential methylation patterns with hypomethylated CpG sites predominantly in preactivated NK cells and in expanded NK cells, independent of cytokine pre-activation.
Conclusions
Our data suggest that the in vitro expansion of NK cells in coculture with K562 cells at least partially recapitulates the memory formation by cytokine-preactivation due to the encounter with K562 cell surface targets prior to being stimulated with cytokines resulting in DNA hypomethylation at a variety of loci in some genes encoding immune system ligands, receptors and regulators such as IL-5, C-C Motif Chemokine Receptor 5 (CCR5) and Programmed Cell Death Ligand 1 (PDL1). Targeted therapy of JAK-class Ph-like ALL with ruxolitinib might interfere with interleukin-signaling pathways in NK cells disrupting memory-formation and cytotoxic activities as shown by live cell imaging and multiparametric full spectrum flow cytometry.
Legal entity responsible for the study
The authors.
Funding
Research institute Children’s Cancer Center and Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display
156TiP - The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Elin Marie Stensland
Session: Poster Display